Literature DB >> 23454283

Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.

Toni-Kim Clarke1, Richard C Crist, Kyle M Kampman, Charles A Dackis, Helen M Pettinati, Charles P O'Brien, David W Oslin, Thomas N Ferraro, Falk W Lohoff, Wade H Berrettini.   

Abstract

The μ-opioid receptor (MOR) binds exogenous and endogenous opioids and is known to mediate the rewarding effects of drugs of abuse. Numerous genetic studies have sought to identify common genetic variation in the gene encoding MOR (OPRM1) that affects risk for drug addiction. The purpose of this study was to examine the contribution of rare coding variants in OPRM1 to the risk for addiction. Rare and low frequency variants were selected using the National Heart Lung and Blood Institute - Exome Sequencing Project (NHLBI-ESP) database, which has screened the exomes of over 6500 individuals. Two SNPs (rs62638690 and rs17174794) were selected for genotyping in 1377 European American individuals addicted to heroin and/or cocaine. Two different SNPs (rs1799971 and rs17174801) were genotyped in 1238 African American individuals addicted to heroin and/or cocaine. Using the minor allele frequencies from the NHLBI-ESP dataset as a comparison group, case-control association analyses were performed. Results revealed an association between rs62638690 and cocaine and heroin addiction in European Americans (p=0.02; 95% C.I. 0.47 [0.24-0.92]). This study suggests a potential role for rare OPRM1 variants in addiction disorders and highlights an area worthy of future study.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454283      PMCID: PMC3640707          DOI: 10.1016/j.neulet.2013.02.018

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

1.  A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women.

Authors:  Howard A Crystal; Sara Hamon; Matthew Randesi; Judith Cook; Kathryn Anastos; Jason Lazar; Chenglong Liu; Leigh Pearce; Elizabeth Golub; Victor Valcour; Kathleen M Weber; Susan Holman; Ann Ho; Mary Jeanne Kreek
Journal:  Addict Biol       Date:  2010-11-11       Impact factor: 4.280

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

3.  Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Authors:  Katarina Drakenberg; Andrej Nikoshkov; Monika Cs Horváth; Pernilla Fagergren; Anna Gharibyan; Kati Saarelainen; Sadia Rahman; Ingrid Nylander; Georgy Bakalkin; Jovan Rajs; Eva Keller; Yasmin L Hurd
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

4.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

5.  Resequencing of nicotinic acetylcholine receptor genes and association of common and rare variants with the Fagerström test for nicotine dependence.

Authors:  Jennifer Wessel; Sarah M McDonald; David A Hinds; Renee P Stokowski; Harold S Javitz; Michael Kennemer; Ruth Krasnow; William Dirks; Jill Hardin; Steven J Pitts; Martha Michel; Lisa Jack; Dennis G Ballinger; Jennifer B McClure; Gary E Swan; Andrew W Bergen
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

6.  Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence.

Authors:  Pingxing Xie; Henry R Kranzler; Michael Krauthammer; Kelly P Cosgrove; David Oslin; Raymond F Anton; Lindsay A Farrer; Marina R Picciotto; John H Krystal; Hongyu Zhao; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2011-06-17       Impact factor: 13.382

7.  Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden.

Authors:  Gavin Bart; Mary Jeanne Kreek; Jurg Ott; K Steven LaForge; Dmitri Proudnikov; Lotta Pollak; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2005-02       Impact factor: 7.853

8.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

9.  Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction.

Authors:  Ishani Deb; Japashish Chakraborty; Prasanta Kumar Gangopadhyay; Susanta Roy Choudhury; Sumantra Das
Journal:  J Neurochem       Date:  2009-11-04       Impact factor: 5.372

10.  Functional characterization of human variants of the mu-opioid receptor gene.

Authors:  Ajay Ravindranathan; Geoff Joslyn; Margaret Robertson; Marc A Schuckit; Jennifer L Whistler; Raymond L White
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-15       Impact factor: 11.205

View more
  16 in total

Review 1.  Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"?

Authors:  Nina Carlier; Victoria S Marshe; Jana Cmorejova; Caroline Davis; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

Review 2.  Genetics of opiate addiction.

Authors:  Brian Reed; Eduardo R Butelman; Vadim Yuferov; Matthew Randesi; Mary Jeanne Kreek
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 3.  Molecular Genetics and New Medication Strategies for Opioid Addiction.

Authors:  Yasmin L Hurd; Charles P O'Brien
Journal:  Am J Psychiatry       Date:  2018-08-02       Impact factor: 18.112

4.  Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Authors:  Tae-Hwi Schwantes-An; Juan Zhang; Li-Shiun Chen; Sarah M Hartz; Robert C Culverhouse; Xiangning Chen; Hilary Coon; Josef Frank; Helen M Kamens; Bettina Konte; Leena Kovanen; Antti Latvala; Lisa N Legrand; Brion S Maher; Whitney E Melroy; Elliot C Nelson; Mark W Reid; Jason D Robinson; Pei-Hong Shen; Bao-Zhu Yang; Judy A Andrews; Paul Aveyard; Olga Beltcheva; Sandra A Brown; Dale S Cannon; Sven Cichon; Robin P Corley; Norbert Dahmen; Louisa Degenhardt; Tatiana Foroud; Wolfgang Gaebel; Ina Giegling; Stephen J Glatt; Richard A Grucza; Jill Hardin; Annette M Hartmann; Andrew C Heath; Stefan Herms; Colin A Hodgkinson; Per Hoffmann; Hyman Hops; David Huizinga; Marcus Ising; Eric O Johnson; Elaine Johnstone; Radka P Kaneva; Kenneth S Kendler; Falk Kiefer; Henry R Kranzler; Ken S Krauter; Orna Levran; Susanne Lucae; Michael T Lynskey; Wolfgang Maier; Karl Mann; Nicholas G Martin; Manuel Mattheisen; Grant W Montgomery; Bertram Müller-Myhsok; Michael F Murphy; Michael C Neale; Momchil A Nikolov; Denise Nishita; Markus M Nöthen; John Nurnberger; Timo Partonen; Michele L Pergadia; Maureen Reynolds; Monika Ridinger; Richard J Rose; Noora Rouvinen-Lagerström; Norbert Scherbaum; Christine Schmäl; Michael Soyka; Michael C Stallings; Michael Steffens; Jens Treutlein; Ming Tsuang; Tamara L Wall; Norbert Wodarz; Vadim Yuferov; Peter Zill; Andrew W Bergen; Jingchun Chen; Paul M Cinciripini; Howard J Edenberg; Marissa A Ehringer; Robert E Ferrell; Joel Gelernter; David Goldman; John K Hewitt; Christian J Hopfer; William G Iacono; Jaakko Kaprio; Mary Jeanne Kreek; Ivo M Kremensky; Pamela A F Madden; Matt McGue; Marcus R Munafò; Robert A Philibert; Marcella Rietschel; Alec Roy; Dan Rujescu; Sirkku T Saarikoski; Gary E Swan; Alexandre A Todorov; Michael M Vanyukov; Robert B Weiss; Laura J Bierut; Nancy L Saccone
Journal:  Behav Genet       Date:  2015-09-21       Impact factor: 2.805

5.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Individual differences in the neuropsychopathology of addiction.

Authors:  Olivier George; George F Koob
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

7.  Next-generation sequencing of human opioid receptor genes based on a custom AmpliSeq™ library and ion torrent personal genome machine.

Authors:  Dario Kringel; Jörn Lötsch
Journal:  Clin Chim Acta       Date:  2016-10-08       Impact factor: 3.786

8.  The frequency of DRD2 rs1076560 and OPRM1 rs1799971 in substance use disorder patients from the United Arab Emirates.

Authors:  Hiba Alblooshi; Gary Hulse; Wael Osman; Ahmed El Kashef; Mansour Shawky; Hamad Al Ghaferi; Habiba Al Safar; Guan K Tay
Journal:  Ann Gen Psychiatry       Date:  2018-06-01       Impact factor: 3.455

Review 9.  Risk Factors and Prevention Strategies for Postoperative Opioid Abuse.

Authors:  Shuai Zhao; Fan Chen; Anqi Feng; Wei Han; Yuan Zhang
Journal:  Pain Res Manag       Date:  2019-07-10       Impact factor: 3.037

10.  Emergent biomarker derived from next-generation sequencing to identify pain patients requiring uncommonly high opioid doses.

Authors:  D Kringel; A Ultsch; M Zimmermann; J-P Jansen; W Ilias; R Freynhagen; N Griessinger; A Kopf; C Stein; A Doehring; E Resch; J Lötsch
Journal:  Pharmacogenomics J       Date:  2016-05-03       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.